R

Biopharmaceutical Research Advances with New c-MET-Targeted Antibody Therapy Pipeline Review - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 14, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Lung cancer, HNSCC, R, Neoplasm, Research, RTK, Medicine, Head, MET, NSCLC, Vaccine, Pharmaceutical industry

The "c-Met-Targeted Antibody Therapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "c-Met-Targeted Antibody Therapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering.
  • The field of oncology research is witnessing a significant advancement with the introduction of a comprehensive review on c-MET-targeted antibody therapy pipeline.
  • Links to the source of information such as press releases, research abstracts, and annual reports further enrich the analysis presented.
  • This review serves as vital reading material for stakeholders aiming to understand the evolving landscape and therapeutic possibilities associated with c-MET-targeted antibody therapy.

IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*

Retrieved on: 
Thursday, December 14, 2023
Biotechnology, Pharmaceutical, General Health, Health, Artificial Intelligence, Infectious Diseases, Technology, Other Health, Transfer, Research, Research and development, Software, MTA, Investment, Risk, Administration, Letter, Intelligence, G&A, Conference, Software as a service, R, Growth, Acosta Sales & Marketing, Video game, Fine chemical, IPA, Service

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for its second quarter of the 2024 fiscal year (“FY24”), which ended October 31, 2023.

Key Points: 
  • IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for its second quarter of the 2024 fiscal year (“FY24”), which ended October 31, 2023.
  • IPA's strategy to offer a fully integrated suite of antibody discovery and development services is showing clear results.
  • In the recent quarter, the Company recorded revenues of $6.2 million and $11.8 million for the three- and six-months ending October 31, 2023, respectively.
  • This is the second consecutive quarter in which we have experienced a year-over-year increase in revenue of approximately $1 million.

Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day

Retrieved on: 
Thursday, December 14, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Webcast, MT1-MMP, Peripheral neuropathy, Brain, Safety, Immune system, Cervical cancer, Food, Therapy, Toxicity, Head, Diabetic neuropathy, Nobel Prize, Patient, CD137, Bicycle, FDA, Non-small-cell lung cancer, Pembrolizumab, Neoplasm, Ionis, Investigational New Drug, Brentuximab vedotin, MUC, ORR, Ovary, Anal cancer, Cancer, Ovarian cancer, Toxic leukoencephalopathy, Pain, R, Drug combination, EV, Central nervous system, TNBC, NSCLC, BRC, Pharmaceutical industry, Vaccine, Birth control, Medical imaging, Thromboxane A2

“In totality, the data support the emerging differentiated profile of our Bicycle® molecules, paving the way to deliver best-in-class or first-in-class therapies for many cancers.

Key Points: 
  • “In totality, the data support the emerging differentiated profile of our Bicycle® molecules, paving the way to deliver best-in-class or first-in-class therapies for many cancers.
  • BT8009 is a Nectin-4 Bicycle toxin conjugate (BTC®) designed to overcome the significant toxicity associated with other toxin conjugate approaches.
  • Over 2024, Bicycle Therapeutics intends to generate early human imaging data from its wholly owned BRC pipeline.
  • Bicycle Therapeutics will continue to develop Bicycle® molecules to address disease outside of oncology through innovative partnerships.

Ocean Power Technologies Sends Letter to Shareholders Highlighting Continued Execution of Company’s Value-Enhancing Strategy

Retrieved on: 
Wednesday, December 13, 2023
Alternative Energy, Energy, Paragon, BOARD, NYSE, Annual general meeting, Telephone, Our Boarding House, Delaware Court of Chancery, OUR, OTC Markets Group, CARD, Broker, Ocean Power Technologies, Multimedia, Bring Your Board!!, Calendar, Marketing, OPT, INTERNET, Veteran, RETURN, Trustee, Internet, R, CPA, Growth, Delaware Court, SIGN, AND, Letter, Noise, Management, Security (finance), Auction, Shareholder

View the full release here: https://www.businesswire.com/news/home/20231213584527/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231213584527/en/
    The full text of the letter is below:
    Thank you for your investment.
  • This year your vote at OPT’s 2023 Annual Meeting – scheduled for January 31, 2024 – is critically important.
  • OPT urges shareholders to vote on the WHITE proxy card to show their support for all the Company’s proposals, including the election of all of the Board of Directors’ (the “Board”) highly qualified director nominees and the continued execution of OPT’s strategy.
  • You may also receive materials from an activist investor, Paragon Technologies, Inc. (“Paragon”) (OTC Pink: PGNT).

Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors

Retrieved on: 
Tuesday, December 12, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Efgartigimod alfa, Senior, Disorder, Florida State University, Hematology, Patient, Eisai, Alexion Pharmaceuticals, Marketing, FA, Muscle weakness, Roche, R, Fanconi anemia, Medication, Amgen, Pharmaceutical industry, Management, Eculizumab

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of R. Keith Woods as an independent, non-executive director to its Board of Directors.

Key Points: 
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of R. Keith Woods as an independent, non-executive director to its Board of Directors.
  • Mr. Woods is a seasoned executive with more than 30 years of experience spanning commercialization, global operations, business strategy and supply chain.
  • “I’m thrilled to welcome Keith to our Board of Directors, who brings deep industry expertise and invaluable experience to the Rocket Board as we build upon our commercial and operational infrastructure to support our anticipated first product launches for severe Leukocyte Adhesion Deficiency (LAD-I) and Fanconi Anemia (FA),” said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharma.
  • Earlier in his career, Mr. Woods held commercial and sales positions of increasing responsibility at Roche, Amgen and Eisai.

International Students Visit China Eastern Airlines

Retrieved on: 
Wednesday, December 13, 2023
Primary, Secondary, Education, Air, Transport, Training, University, R, Aviation, VR, A350, Student, Airline, SkyTeam, Tourism, China Eastern Airlines

Nearly 30 overseas students joined an educational tour at R&D Center of China Eastern Airlines on Dec. 8, where they had an opportunity to get close to the aviation culture and feel its charm.

Key Points: 
  • Nearly 30 overseas students joined an educational tour at R&D Center of China Eastern Airlines on Dec. 8, where they had an opportunity to get close to the aviation culture and feel its charm.
  • After receiving commemorative gifts from staff of China Eastern Airlines, the students wrapped up this visit.
  • It is reported that China Eastern Airlines has established direct connections to 86 international destinations, covering 31 countries and regions worldwide.
  • With the support of the SkyTeam Alliance, China Eastern Airlines' route network extends to 1,050 destinations in 166 countries and regions, and it has established over 100 overseas offices.

NOVA Infrastructure Fund I Completes Eighth Platform Investment With Acquisition of A&R Bulk-Pak

Retrieved on: 
Tuesday, December 12, 2023
Manufacturing, Logistics, Supply Chain Management, Transport, Packaging, Chemicals, Plastics, Foot, Jones Day, Harbor, Acquisition, Safety, CSX, NOVA, Partner, Han Kun Law Offices, Port of Charleston, Partnership, P.C, R, Growth, South Carolina Ports Authority, Law, A&R, Pleasure, Port

NOVA Infrastructure (“NOVA”), a middle-market infrastructure investment firm, today announced the acquisition of A&R Bulk-Pak (“A&R”), a South Carolina-based provider of contract packaging, transloading, warehousing, and other critical supply chain services for the petrochemical industry.

Key Points: 
  • NOVA Infrastructure (“NOVA”), a middle-market infrastructure investment firm, today announced the acquisition of A&R Bulk-Pak (“A&R”), a South Carolina-based provider of contract packaging, transloading, warehousing, and other critical supply chain services for the petrochemical industry.
  • This strategic investment positions A&R to usher in its next stage of growth and continue to serve leading global chemical providers.
  • Harbor, a portfolio company of NOVA, is a leading provider of transportation, logistics and warehousing services in Charleston, South Carolina.
  • The agreement aligns Harbor, A&R and NOVA as long-term partners to deliver a broader suite of comprehensive supply chain solutions in North America.

BioLabs and Promega Announce Collaboration to Support Young Biotech Companies

Retrieved on: 
Wednesday, December 13, 2023
Health, Genetics, Other Science, Research, Science, Pharmaceutical, Biotechnology, R, Biolab, Incubator, Knowledge, Partnership, Promega

BioLabs and Promega today announced the expansion of their collaborative efforts to accelerate life science innovation worldwide through support for early-stage start-up companies.

Key Points: 
  • BioLabs and Promega today announced the expansion of their collaborative efforts to accelerate life science innovation worldwide through support for early-stage start-up companies.
  • Promega GmbH in Walldorf, the German branch of global life science manufacturer Promega, will provide equipment, services and training to BioLabs Heidelberg.
  • The global exchange of knowledge between the start-ups and Promega scientists plays a central role, underscoring why Promega prioritizes support for incubators such as BioLabs, says Dr. Hans-Joachim Mueller, General Manager of Promega GmbH.
  • “We can bring Promega products directly into the development process of start-up companies so they can more quickly bring their technologies to market.”
    Nicolas Bardonnet, General Manager of Promega France, says Promega support of BioLabs in Europe is reaffirmed by outcomes witnessed in the US.

Aiolos Bio Strengthens and Expands Leadership Team with Key Appointments

Retrieved on: 
Tuesday, December 12, 2023
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, COPD, Atlas Venture, Entrepreneurship, DBV Technologies, Rockefeller University, Investment, PD, Respiratory system, Patient, Strategic planning, Element, Doctor of Philosophy, M&A, Galvani Bioelectronics, GSK, MedImmune, Caregiver, Atopic dermatitis, R, Publishing, Atlas, McKinsey & Company, Asthma, Pharmaceutical industry, Neuroscience, Aeolus, Genentech

“We are delighted to welcome René and Tapan as key members of our leadership team at this exciting time for the Company as we prepare to initiate a Phase 2 clinical trial for our lead drug candidate, AIO-001, in moderate-to-severe asthma patients,” said Khurem Farooq, Co-Founder and Chief Executive Officer of Aiolos Bio.

Key Points: 
  • “We are delighted to welcome René and Tapan as key members of our leadership team at this exciting time for the Company as we prepare to initiate a Phase 2 clinical trial for our lead drug candidate, AIO-001, in moderate-to-severe asthma patients,” said Khurem Farooq, Co-Founder and Chief Executive Officer of Aiolos Bio.
  • “I’m thrilled to be joining the talented team at Aiolos Bio,” said Dr. Van der Merwe.
  • We look forward to presenting and publishing data in 2024.” Dr. Van der Merwe will join Aiolos Bio effective January 2,2024.
  • He joins Aiolos Bio from Bain Capital Life Sciences where he led and managed investments across therapeutic areas.

ISG to Publish Reports on Chemical Industry Services, Solutions

Retrieved on: 
Friday, December 8, 2023
Software, Mobile, Wireless, Networks, Professional Services, Hardware, Data Management, Technology, Security, Chemicals, Plastics, Other Technology, Consulting, Manufacturing, Carbon, Data management, Research, EVS, Chemical industry, Blockchain, ISG, CX, Digital, URL, R, Innovation, Transport, Cryptocurrency, Online shopping

The results of this first-time study will be published in two comprehensive ISG Provider Lens™ reports, titled Chemical Industry Services and Solutions, scheduled to be released in May 2024.

Key Points: 
  • The results of this first-time study will be published in two comprehensive ISG Provider Lens™ reports, titled Chemical Industry Services and Solutions, scheduled to be released in May 2024.
  • The global chemical industry is facing a challenging year with geopolitical tensions, commodity price fluctuations and supply and demand issues plaguing the value chain.
  • “Emerging technologies such as blockchain, quantum computing and high-performance computing are also impacting industry digitization and providing opportunities for technology partners.”
    ISG has distributed surveys to more than 50 chemical industry services and solutions providers.
  • Geographically focused reports from the study will examine chemical industry services and solutions available in North America and Europe.